A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorChina-Japan Friendship Hospital

About this trial

Establish a cohort of diabetic kidney disease(DKD) patients with intensive weight loss treatment to evaluate the impact of intensive weight loss treatment on the renal prognosis of DKD and construct a prediction model for the improvement of renal outcomes after weight loss.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 65 years old;

BMI>25Kg/m2 or abdominal obesity (i.e. waist circumference>90cm for men and>85cm for women);

eGFR<30ml/min/1.73m2 or urinary microalbumin≥300mg/g, eGFR<60ml/min/1.73m2.

Disqualifiers

Patients who are taking glucocorticoids;

Combined with tumors; ③Combined with autoimmune diseases; ④Serum albumin<25g/L.

Trial population

Obese patients with DKD treated with intensive weight loss or traditional treatment

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Bariatric surgery

    Procedure/Surgery

    Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function

  • Non-surgical therapy

    Other intervention

    Diet management,exercise,metformin,GLP-1 receptor agonists and other drugs which can lose weight.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Surgical group2 interventions
Group B: Non-surgical group1 intervention

Trial outcomes

Primary outcomes

1

Total weight loss

Time frame
1st, 3rd, 6th and 12th month after intervention, respectively.

Secondary outcomes

1

Serum creatinine

Time frame
1st, 3rd, 6th and 12th month after intervention, respectively.
2

Glomerular filtration rate

Time frame
1st, 3rd, 6th and 12th month after intervention, respectively.
3

Fasting blood glucose

Time frame
1st, 3rd, 6th and 12th month after intervention, respectively.
4

Average blood glucose from continuous glucose monitoring

Time frame
1st, 3rd, 6th and 12th month after intervention, respectively.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.